2024-516122-66-00招募中2 期
A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 170
- 试验地点
- 12
- 主要终点
- TFR1 stage: BCR-ABL ≤ 0.1% (IS) 96 weeks after the start of consolidation. TFR2 stage: BCR-ABL ≤ 0.1% (IS) 48 weeks after the start of TFR2.
研究概览
简要总结
TFR1 stage: To determine the percentage of patients in full treatment-free remission 96 weeks after the start of consolidation. Full Treatment-Free Remission (FTFR) is defined as patients with Major Molecular Response (MMR) or better, including those who have totally discontinued treatment during the Treatment-Free Remission (TFR) phase and those who are treated with half the standard dosage. TFR2 stage: To estimate the percentage of patients in treatment-free remission 48 weeks after starting a second attempt at treatment-free remission (TFR2). Treatment-Free Remission (TFR) is defined as patients with Major Molecular Response (MMR) or better.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Tfr2 Stage
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •TFR1 stage: Male and female patients 18 years or older.
- •Male and female patients 18 years or older.
- •Diagnosis of CP-CML according to the WHO and no previous history of progression to AP/BP CML.
- •First-line treatment with nilotinib for at least 3 calendar years, followed by first TFR attempt.
- •Failed first TFR attempt followed by at least 1 year of nilotinib retreatment before enrollment in TFR2 stage.
- •MR4 or better (BCR-ABL ≤ 0.01% IS) assessed at screening.
- •Patient must meet the following laboratory values at the reinduction screening visit: a. Absolute neutrophil count ≥1.0 x 109/L b. Platelets ≥75 x 109/L c. Hemoglobin (Hgb) ≥ 9 g/dL d. Serum creatinine < 1.5 mg/dL e. Total bilirubin ≤ 2 x ULN except for patients with Gilbert’s syndrome who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN f. AST ≤ 3.0 x ULN g. ALT ≤ 3.0 x ULN h. Alkaline phosphatase ≤ 2.5 x ULN i. Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis j. Serum levels of potassium, magnesium, total calcium within the normal limits. Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed.
- •ECOG performance status 0-
- •Study subjects must be able to comply with study procedures and follow-up examinations.
- •Diagnosis of CML-CP according to the World Health Organization.
- •Patients with CML-CP under first-line treatment with nilotinib at the approved daily dose of 300 mg BID mg for at least 3 calendar years. Note: At study entry, an ongoing treatment at a dose ≥400 mg per day is allowed.
- •Sustained DMR defined as ≥ MR 4.0 (BCR-ABL level ≤0.01% IS) in all of the last 4 BCR-ABL RQ-PCR assessments with a minimum interval between each assessment of 3 months and a maximum interval of 6 months.
- •Patient must meet the following laboratory values at the screening visit: • Absolute Neutrophil Count ≥1.0 x 109/L • Platelets ≥75 x 109/L • Hemoglobin (Hgb) ≥ 9 g/dL • Serum creatinine < 1.5 mg/dL • Aspartate transaminase (AST) ≤ 3.0 x Upper Limit of Normal (ULN) • Alanine transaminase (ALT) ≤ 3.0 x ULN • Serum lipase ≤ 2 x ULN
- •Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Study subjects must be able to comply with study procedures and follow-up examinations.
- •Signed informed consent to the TFR1 stage from the patient or from his/her legal representative.
- •TFR2 stage: Signed informed consent to the TFR2 stage from the patient or from his/her legal representative.
排除标准
- •TFR1 stage: Patients with known atypical transcript.
- •Patients who have not recovered from prior surgery.
- •Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).
- •Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry.
- •Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo.
- •Pregnant or nursing (lactating) women.
- •Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 14 days after stopping medication. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with nilotinib during pregnancy.
- •TFR2 stage: Patients with known atypical transcript.
- •CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past).
- •Dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months.
- •CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past).
- •Known impaired cardiac function including any one of the following: • Inability to determine QT interval on ECG • Complete left bundle branch block • Long QT syndrome or a known family history of long QT syndrome • History of or presence of clinically significant ventricular or atrial tachyarrhythmias • Clinically significant resting bradycardia • QTcF > 450 msec (male) or > 460 msec (female) • History or clinical signs of myocardial infarction within 1 year prior to study entry • History of unstable angina within 1 year prior to study entry • Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension)
- •Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.
- •History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis.
- •Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer.
- •History of other active malignancy within 5 years prior to study entry except for previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively.
- •Patients who have not recovered from prior surgery.
- •Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks.
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).
- •Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry.
- •Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo.
- •Dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months.
- •Pregnant or nursing (lactating) women.
- •Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 14 days after stopping medication. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with nilotinib during pregnancy
- •Patient ever attempted to permanently discontinue nilotinib treatment.
- •Known impaired cardiac function including any one of the following: • Inability to determine QT interval on ECG • Complete left bundle branch block • Long QT syndrome or a known family history of long QT syndrome • History of or presence of clinically significant ventricular or atrial tachyarrhythmias • Clinically significant resting bradycardia • QTcF > 480 msec • History or clinical signs of myocardial infarction within 1 year prior to study entry • History of unstable angina within 1 year prior to study entry • Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension)
- •Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.
- •History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis.
- •Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer.
- •History of other active malignancy within 5 years prior to study entry except for previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively.
结局指标
主要结局
TFR1 stage: BCR-ABL ≤ 0.1% (IS) 96 weeks after the start of consolidation. TFR2 stage: BCR-ABL ≤ 0.1% (IS) 48 weeks after the start of TFR2.
TFR1 stage: BCR-ABL ≤ 0.1% (IS) 96 weeks after the start of consolidation. TFR2 stage: BCR-ABL ≤ 0.1% (IS) 48 weeks after the start of TFR2.
次要结局
- TFR1 stage: Sustained DMR is defined as no loss of MR4.0 (BCR-ABL level ≤ 0.01% IS) in any BCR-ABL RQ-PCR assessment. The proportion of patients in sustained DMR at the end of consolidation (week 48) is calculated by dividing the number of patients in sustained DMR at week 48 by the number of patients who entered the consolidation period.
- DMR: ≥ MR 4.0 (BCR-ABL level ≤0.01% IS) at week 48, 96 and 144 after the start of the consolidation period. The proportion of patients in deep molecular response is calculated by dividing the number of patients in DMR 48, 96 and 144 weeks after the start of consolidation by the number of patients who entered the consolidation period.
- BCR-ABL ≤ 0.1% (IS) 144 weeks after consolidation. The proportion of patients in full treatment-free remission at week 144 is calculated by dividing the number of patients with no loss of MMR 144 weeks after the start of consolidation by the number of patients who entered the consolidation period.
- BCR-ABL ≤ 0.1% (IS) 48, 96, 144 weeks after the start of the consolidation. The proportion of patients with MMR at week 48, 96 and 144 is calculated by dividing the number of patients with MMR at week 48, 96 and 144, regardless of whether they required re-initiation of treatment after the start the study, by the number of patients who entered the consolidation.
- BCR-ABL transcript levels (IS) after restart of nilotinib therapy in patients who failed TFR1.
- BCR-ABL transcript levels (IS) after discontinuation of nilotinib therapy in patients in TFR1.
- BCR-ABL transcript levels (IS) during consolidation.
- FTFS: time from the start of consolidation to the earliest occurrence of any of the following events: loss of MMR, reinitiation of treatment due to any cause, progression to accelerated phase (AP)/blast crisis (BC), or death due to any cause.
- TFR rate: proportion of patients among those who entered TFR1 with no loss of MMR and no reinitiation of nilotinib after drug discontinuation at weeks 96 and 144 after the start of consolidation. The proportion of patients in TFR1 at weeks 96 and week 144 is calculated by dividing the number of patients with no loss of MMR and no reinitiation of nilotinib after drug discontinuation at weeks 96 and week 144 by the number of patients who entered TFR1.
- TFS: time from the start of TFR1 to the earliest occurrence of any of the following events: loss of MMR, reinitiation of treatment due to any cause, progression to AP/BC or death due to any cause.
- PFS: time from the start of consolidation to progression to AP/BC or death due to any cause, whichever occurs first.
- PFS: time from the start of TFR1 to progression to AP/BC or death due to any cause, whichever occurs first.
- OS: time from start of the study to death due to any cause.
- Type, frequency and severity of adverse events, laboratory values that fall outside of the pre-determined ranges and clinically notable ECG and other safety data during nilotinib treatment consolidation, TFR1, and during reinitiation of treatment with nilotinib.
- Successful FTFR and TFR - no loss of MMR and no reinitiation of nilotinib therapy in the first 96 weeks following the study start.
- Framingham risk score and SCORE at baseline
- TFR2 stage: Eligibility is defined as sustained DMR, defined as no loss of MR4.0 (BCR-ABL level ≤ 0.01% IS) in any BCR-ABL RQ-PCR assessment. The proportion of eligible patients is calculated by dividing the number of eligible patients by the number of patients who entered reinduction.
- DMR: ≥ MR 4.0 (BCR-ABL level ≤0.01% IS); MMR: (BCR-ABL level ≤0.1% IS). The proportion of patients who regain MMR/DMR is calculated by dividing the number of patients in MMR/DMR 48 weeks after the start of TFR2 by the number of patients with loss of MMR in TFR2.
- BCR-ABL transcript levels (IS) during reinduction.
- BCR-ABL transcript levels (IS) after restart of nilotinib therapy in patients who failed TFR2 period.
- BCR-ABL transcript levels (IS) after restart of nilotinib therapy in patients who were not eligible for entering the TFR2 period.
- BCR-ABL transcript levels (IS) after discontinuation of asciminib + nilotinib therapy in patients in TFR2.
- TFS: time from the start of TFR2 stage to the earliest occurrence of any of the following events: loss of MMR, reinitiation of treatment due to any cause, progression to AP/BC or death due to any cause.
- PFS: time from the start of TFR2 stage to progression to AP/BC or death due to any cause, whichever occurs first.
- OS: time from start of reinduction to death due to any cause.
- Type, frequency and severity of adverse events, laboratory values that fall outside of the pre-determined ranges and clinically notable ECG and other safety data after the start of reinduction.
- Successful TFR2 - no loss of MMR and no reinitiation of nilotinib therapy starting from reinduction for TFR2.
- Framingham risk score and SCORE at the start of reinduction.
研究者
Alessandra Misto
Scientific
Novartis Farma S.p.A.
研究点 (12)
Loading locations...
相似试验
招募中
2 期
CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomicsAcute Myeloid Leukemia2022-500295-60-00Centre Hospitalier Universitaire De Nice210
招募中
2 期
NaDeJ (National Deescalation Study One)2024-517832-23-00Vychodoslovensky Onkologicky Ustav a.s.100
招募中
3 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC2022-500395-57-00Merck Sharp & Dohme Corp.267
招募中
2 期
Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver2024-517204-11-00Fondation Franc.Cancerologie Digestive52
招募中
4 期
Complete Remission After Treatment With Biologics for Nasal PolypsNCT07268313Rigshospitalet, Denmark66